최고 Blood Cancer 팟캐스트 (2024)

1
Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal 35:28

20h ago35:28

35:28

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: · Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated · Low risk: No prior th…

1
Christian Divorce: Adrian and Dave Bish in Conversation 52:03

1d ago52:03

52:03

The response to my series on divorce and remarriage and Dave Bish's sermon have been hugely encouraging. We thought it might be interesting to have a podcast style conversation about it. I hope this will be helpful for you if you are going through divorce right now, if you did so years ago, or if you would like to learn how to better support others…

1
Episode 42. CAR T-cell Therapy in Early Relapsed Myeloma with Dr. Samer Al Hadidi 54:49

23d ago54:49

54:49

In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-ce…

1
Episode 41. Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi 47:22

1M ago47:22

47:22

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 40. Management of Newly Diagnosed AL Amyloidosis with Dr. Angela Dispenzieri 52:34

2M ago52:34

52:34

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://…

1
Episode 39. ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel 55:14

2M ago55:14

55:14

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitini…

1
Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan 52:10

3M ago52:10

52:10

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate,…

1
Episode 37. ASH 2023 Myeloma Recap with Dr. Ben Derman 1:01:40

4M ago1:01:40

1:01:40

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper…

1
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre 50:59

4M ago50:59

50:59

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax…

1
Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson 1:08:40

5M ago1:08:40

1:08:40

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed…

1
Episode 34. Management of FLT3 AML with Dr. Alexander Perl 1:08:19

5M ago1:08:19

1:08:19

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nej…

1
Episode 33. The art of caring for patients at the end of life with Dr. Azra Raza 59:15

6M ago59:15

59:15

In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/d…

1
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser 58:50

6M ago58:50

58:50

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes: 1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/R…

1
Episode 31. Management of CNS Lymphoma 51:40

7M ago51:40

51:40

In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 2. Elizabe…

1
Episode 30. Management of High-Risk Myeloma 1:08:29

7M ago1:08:29

1:08:29

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon: 1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL: https://pubmed.ncbi.nlm.nih.gov/37315268/ 2. Meta-analysi…

1
Episode 29. Management of Peripheral T-Cell Lymphoma 56:13

8M ago56:13

56:13

In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma…

1
Episode 28. Management of CCUS 47:54

8M ago47:54

47:54

In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes: 1. CCUS and risk of transformation to myeloid neoplasms: https://www.sc…

1
Episode 27. Management of PNH 1:03:29

9M ago1:03:29

1:03:29

In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode: How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/ Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired sev…

1
Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma 57:26

9M ago57:26

57:26

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University. Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS Here are the key trials we discussed: 1. RATHL Trial (PET-adapted treatment of Adva…

1
Episode 25. Managing Acute Toxicities of CAR T-cell Therapy 49:08

10M ago49:08

49:08

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center. Here are some of the key articles we discussed: 1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: ht…

1
Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma 47:30

10M ago47:30

47:30

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes: 1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9 2. RCTs of BCMA CAR T-cell Therap…

1
Episode 23. Bispecific Antibodies in Myeloma 51:35

11M ago51:35

51:35

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed: 1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/ 2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619 3. Ta…

1
Episode 22. Management of Low-Risk MDS 1:03:46

11M ago1:03:46

1:03:46

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed: 1. ASH choosing wisely: https://www.hematolo…

1
Episode 21. Newly Diagnosed Mantle Cell Lymphoma 46:05

12M ago46:05

46:05

In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes: 2:11 How to diagnose mantle cell lymphoma (MCL)? 6:51 Clinical manifestations of mantle cell lymphoma 7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with l…

1
Episode 20. Management of Myeloma in LMICs 57:25

1y ago57:25

57:25

In this episode, we discuss the management of multiple myeloma in LMICs with Dr. Andrés Gómez-De León from UANL, Monterrey, Mexico, and Dr. Aditya Jandial from PGIMER, Chandigarh, India. This episode was inspired by an article in Lancet Haematology titled “The Underrepresented Majority”, which highlighted the lack of access to some of the basic ant…

1
Episode 19. Management of Primary Myelofibrosis 59:16

1y ago59:16

59:16

In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode: 1. Risk stratification of PMF: MIPSS70 Score: http://www.mipss70score.it https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886 Gene…

1
Episode 18. Management of Smoldering Multiple Myeloma 46:32

1y ago46:32

46:32

1. How I Approach Smoldering Myeloma (Vaxman and Gertz): https://ashpublications.org/blood/article/140/8/828/485274 2. Risk-Stratification Models in SMM: Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/ PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/ PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/ IMWG SMM model…

1
Episode 17. Acquired Aplastic Anemia 46:29

1y ago46:29

46:29

In this episode, we discuss the management of acquired aplastic anemia with Dr. Amy DeZern. Here are the links to some of the key articles discussed in this show: 1. Review article on aplastic anemia: https://www.nejm.org/doi/10.1056/NEJMra1413485 2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia: https://…

1
Episode 16. ASH 2022 Leukemia and Myeloid Malignancies Recap 55:12

1y ago55:12

55:12

1. Phase III ASAP trial https://ash.confex.com/ash/2022/webprogram/Paper159962.html 2. Phase III Dauno-Double Trial https://ash.confex.com/ash/2022/webprogram/Paper157126.html 3. Reduced venetoclax exposure: https://ash.confex.com/ash/2022/webprogram/Paper165464.html 4. Menin Inhibitors in AML https://ash.confex.com/ash/2022/webprogram/Paper164849.…

1
Episode 15. Management of Newly Diagnosed DLBCL (Including Bonus ASH22 Updates) 53:44

1y ago53:44

53:44

In this episode, we discuss the management of newly diagnosed DLBCL with Dr. Pallawi Torka. We also have a few bonus ASH22 updates on DLBCL. Links to articles and abstracts discussed in the episode are as follows: 1. A comprehensive review article on DLBCL: https://pubmed.ncbi.nlm.nih.gov/33657296/ 2. RCT testing CHOP vs Three Intensive Regimens in…

1
Episode 14. MRD in Multiple Myeloma 53:55

1y ago53:55

53:55

1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-4 2. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/ 3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outco…

1
Episode 13. Management of Newly Diagnosed Younger Adults with AML 49:06

1+ y ago49:06

49:06

Study showing the time from diagnosis of AML to the start of intensive treatment indicate that a treatment delay has no negative prognostic impact. https://ashpublications.org/blood/article/136/7/823/460669/Does-time-from-diagnosis-to-treatment-affect-the RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy…

1
Episode 12. ASH 2022 Myeloma Recap 1:02:43

1+ y ago1:02:43

1:02:43

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper159606.html https://ash.confex.com/ash/2022/webprogram/Paper168930.html 2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model. h…

1
Episode 11. ASH22 Recap: Lymphoma and CLL 39:02

1+ y ago39:02

39:02

ALPINE Trial: Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL (https://www.nejm.org/doi/full/10.1056/NEJMoa2211582) CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html) AVO Trial:…

1
Episode 10. Castleman Disease 56:22

1+ y ago56:22

56:22

Excellent overview of Castleman Disease: https://ashpublications.org/blood/article/135/16/1353/452573/Overview-of-Castleman-disease International consensus guideline for treatment of Idiopathic Multicentric Castleman Disease (iMCD): https://ashpublications.org/blood/article/132/20/2115/39506/International-evidence-based-consensus-treatment Somatic …

1
Episode 9. CAR-T cell therapy in Lymphoma 51:17

1+ y ago51:17

51:17

In this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy: Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447 Tisagenlecleucel (tisa-cel) https://www.nejm…

1
Episode 8. Management of Newly Diagnosed CLL 1:02:40

1+ y ago1:02:40

1:02:40

Key articles and trials discussed in the episode: 1. Excellent review in NEJM on treatment of CLL (2020): https://www.nejm.org/doi/full/10.1056/NEJMra1908213 2. Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1812836 3. E1912 (Ibrutinib vs chemoimmunotherapy in young…

1
Episode 7. Newly Diagnosed Ph-negative ALL 48:05

1+ y ago48:05

48:05

Key papers discussed in the show: 1. Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and 2. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://a…

1
Episode 6. Donor Search for Allogeneic Hematopoietic Stem Cell Transplant 48:16

1+ y ago48:16

48:16

Key papers discussed in the show: 1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/ 2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa1500140 3. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.03502 4. Review/pers…

1
Episode 5. Mentorship and Career Development 40:57

1+ y ago40:57

40:57

In this episode, we do a thought provoking discussion with Dr. Marty Tallman on mentorship and career development in academic hematology and medical oncology. A must listen for all trainees and early career clinical investigators. Sage wisdom from a legend in the field!저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 4. Measurable Residual Disease in AML 1:02:50

1+ y ago1:02:50

1:02:50

2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/ Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 3. Management of Waldenström Macroglobulinemia 46:11

1+ y ago46:11

46:11

https://ascopubs.org/doi/abs/10.1200/JCO.22.00495저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 2. CAR T-Cell Therapy in Multiple Myeloma 31:32

1+ y ago31:32

31:32

In this episode, we discuss with Dr. Surbhi Sidana the latest advances, practical aspects of patient management, and future directions of cellular therapies in multiple myeloma.저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Episode 1. Implications of Clonal Hematopoiesis 50:50

2y ago50:50

50:50

In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.저자 Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

1
Introduction to BloodCancerTalks 2:19

2y ago2:19

2:19

BloodCancerTalks is a new podcast focusing exclusively on hematologic malignancies. We will bring a wide range of experts to dig deep into specific topics and critically appraise the literature. Raj Chakraborty is a hematologist/oncologist and an Assistant Professor of Medicine at Columbia University. Ash Kishtagari is a hematologist/oncologist and…

1
Immunology for blood cancer patients a Q and A session with Dr S. Shahzad Mustafa 1:16:57

2y ago1:16:57

1:16:57

We explore issues related to our risk of infections including COVD-19. Some of the issues we discuss are controversial and others would have different opinions. Each of us have to make our own decisions in consultation with our own doctors. --- Send in a voice message: https://podcasters.spotify.com/pod/show/adrian-warnock/message…

1
NEW treatments for COVID19 that might save your life and how to get them 17:16

2+ y ago17:16

17:16

Worried about omnicrom? Listen to this update on our four step plan to keep blood cancer patients and others with imnmune compromise safe: Warn, Test, Protect, Treat. Monoclonal antibodies and antivirals rapidly becoming available. Find out how YOU can get them. LEARN MORE AT https://bloodcanceruncensored.com/?s=COVID --- Send in a voice message: h…

1
How do you recover from an acute and aggressive blood cancer? 50:02

2+ y ago50:02

50:02

Adrian interviews El who spent the COVID19 pandemic being treated for Hodgkin Lymphoma. --- Send in a voice message: https://podcasters.spotify.com/pod/show/adrian-warnock/message

1
Biosimilars with Dr. Gary Lyman 32:06

3y ago32:06

32:06

Existing biosimilars are safe, effective alternatives to their reference biologics, and are increasingly being incorporated into oncology treatment guidelines. Technological advances that have emerged in the years since biologic agents entered the market allow for the careful assessment of “critical clinical attributes” of biosimilar agents. This h…

1
Advanced bladder cancer: Dr. Arjun Balar talks treatment strategies in a changing field 27:25

3y ago27:25

27:25

Systemic treatment for advanced urothelial cancer is quickly evolving. On this week’s podcast, Arjun Balar, MD, director of the genitourinary medical oncology program at New York University discusses his approach amid changing times with guest host Alan Lyss, MD, a community-based medical oncologist and clinical researcher in the St. Louis area bef…

들어볼 가치가 있는 팟캐스트

Blood Cancer 팟 캐스트

들어볼 가치가 있는 팟캐스트

빠른 참조 가이드